Advertisement


Sherene Loi, MD, on Triple-Negative Breast Cancer: A Pooled Data Analysis

2015 San Antonio Breast Cancer Symposium

Advertisement

Sherene Loi, MD, of Peter MacCallum Cancer Centre, discusses a pooled individual patient data analysis of stromal tumor-infiltrating lymphocytes in primary triple-negative breast cancer treated with anthracycline-based chemotherapy (Abstract S1-03).



Related Videos

Breast Cancer

Matthew J. Ellis, PhD, FRCP: Update on Translational Research

Matthew J. Ellis, PhD, FRCP, of the Baylor College of Medicine, gives his expert perspective on this evolving area of research.

Breast Cancer

Lori Pierce, MD, on Breast Cancer Radiotherapy: Late Side Effects

Lori J. Pierce, MD, of the University of Michigan Health System, discusses findings on second cancer incidence and non-breast cancer mortality among 40,000 women in 75 clinical trials. (Abstract S5-08)

Breast Cancer

Jame Abraham, MD, on The JAVELIN and KEYNOTE-028 Study Results

Jame Abraham, MD, of the Cleveland Clinic, discusses findings on the use of avelumab, an anti–PD-L1 antibody, in patients with locally advanced or metastatic breast cancer, as well as the preliminary efficacy and safety findings of pembrolizumab in patients with PD-L1–positive, estrogen receptor–positive/HER2-negative disease (Abstracts S1-04, S5-07).

Breast Cancer

Jame Abraham, MD, on HER2-Positive Breast Cancer: Results of the BCIRG-006 Study

Jame Abraham, MD, of the Cleveland Clinic, discusses the 10-year follow-up of this trial, and the long-term benefit and safety of adding trastuzumab to the adjuvant treatment of HER2-positive early breast cancer (Abstract S5-04).

Breast Cancer

William M. Sikov, MD, FACP, on Triple-Negative Breast Cancer: Results of the CALGB Alliance Trial

William M. Sikov, MD, of Women and Infants Hospital of Rhode Island, discusses the results of this study that showed pathologic complete response to presurgery chemotherapy improved survival (Abstract S2-05).

Advertisement

Advertisement




Advertisement